Taiho terminates Phase III liver cancer trial
This article was originally published in Scrip
Executive Summary
Taiho Pharmaceutical (part of Otsuka) is terminating the Phase III ORIENTAL trial of the angiogenesis inhibitor TSU-68 (orantinib) in patients with hepatocellular carcinoma.